A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; Etoposide; Rituximab; Topotecan; Vincristine
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 06 Nov 2019 Results (n=29, As of May 30, 2019) released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 09 Jul 2019 Planned primary completion date changed from 25 Apr 2021 to 7 Apr 2022.
- 20 Nov 2018 Planned number of patients changed from 135 to 165.